Migration of dermal cells expressing a macrophage C-type lectin during the sensitization phase of delayed-type hypersensitivity.
Dermal cells expressing a macrophage C-type lectin (mMGL) were previously suggested to migrate to regional lymph nodes during the sensitization phase of delayed-type hypersensitivity (DTH). The migration seemed to be induced by the solvent used to dissolve the antigen, and the DTH response was significantly enhanced by the migration. In this study, immunohistochemical analysis of skin after epicutaneous application of one of such solvents, a mixture of acetone and dibutylphthalate (AD), revealed a transient decrease in the number of mMGL-positive cells in the dermis. A similar decrease in this cell population was also observed in an ex vivo assay with skin explants excised from AD-treated sites. Conditioned medium from organ culture of AD-treated skin induced a similar decrease of mMGL-positive cells in untreated dermis, indicating the involvement of soluble factors. mMGL-positive cells seemed to represent a unique subpopulation of F4/80-positive dermal cells.
Chun
K H
KH
Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan.
Imai
Y
Y
Higashi
N
N
Irimura
T
T
D000096:Acetone / Q000008:administration & dosage / Q000494:pharmacology; D000279:Administration, Cutaneous; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000943:Antigens, Differentiation / Q000032:analysis; D001212:Asialoglycoproteins; D001685:Biological Factors / Q000737:chemistry / Q000302:isolation & purification / Q000502:physiology; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D002465:Cell Movement / Q000187:drug effects; D048429:Cell Size; D017077:Culture Media, Conditioned / Q000494:pharmacology; D017449:Dermatitis, Allergic Contact / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D020405:Dermis / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D003993:Dibutyl Phthalate / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D007116:Immunization, Passive; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000276:immunology; D037102:Lectins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D037181:Lectins, C-Type; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008565:Membrane Proteins; D051379:Mice; D008813:Mice, Inbred ICR; D008970:Molecular Weight; D009924:Organ Culture Techniques; D012997:Solvents / Q000008:administration & dosage / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D001212:Asialoglycoproteins; D001685:Biological Factors; D002352:Carrier Proteins; C064720:Clec10a protein, mouse; D017077:Culture Media, Conditioned; D007375:Interleukin-1; D037102:Lectins; D037181:Lectins, C-Type; D008565:Membrane Proteins; D012997:Solvents; C036763:monocyte-macrophage differentiation antigen; D000096:Acetone; D003993:Dibutyl Phthalate